Overview of Local Side Effects of Prostaglandin Analogues in Patients with Primary Open-Angle Glaucoma

Gar'kavenko V. V.
MD, PhD, Department Head¹

Kireeva E. A.
MD, Ophtalmologist¹

Epova E. V.
MD, Ophtalmologist¹

Balashova P. M.
MD, Assistant, Chair for Ophtalmology², Ophtalmologist¹

1 - P.G. Makarov Krasnoyarsk Regional Ophthalmological Clinical Hospital, Krasnoyarsk, Russian Federation
2 - V.F. Vojno-Yaseneckij Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation

Gar'kavenko Viktor; e-mail: victor-unique@yandex.ru.

None declared.

The study had no sponsorship.

A brief review of the hypotensive effect of prostaglandin analogs is presented. The history of the appearance of the molecule of the first of prostaglandin analogues, latanoprost, is touched upon. All groups of prostaglandin analogs presented on the Russian market, their mechanisms of action and positive effects are considered. Possible local side effects having a pronounced negative impact on compliance, as well as possible cosmetic defects, including issues affecting the duration and effectiveness of surgical treatment, are described in more detail.

prostaglandin analogs, hyperemia of the conjunctiva, eyelash growth, change in the color of the iris, prostaglandin-associated periorbitopathy

10.29234/2308-9113-2022-10-3-53-62

1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021; 9(2): e144-e160, doi: 10.1016/S2214-109X(20)30489-7

2. Tham Y.C., Li X., Wong T.Y., Quigley H. A.,  Aung T., Cheng Ch. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11): 2081-2090, doi: 10.1016/j.ophtha.2014.05.013

3. Thelen U. Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost-Timolol Fixed-Dose Combination versus Preservative-Free Latanoprost-Timolol Fixed-Dose Combination Therapy: Real-World Experience. Journal of Ophthalmology and Research 2022; 5(1): 24-28.

4. Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992; 17: 691-704, doi: 10.1358/dof.1992.017.08.187766

5. Astahov Yu.S., Nechiporenko P.A. Analogi prostaglandinov: proshloe, nastoyashchee i budushchee. [Prostaglandin analogues: past, present and future.] Oftal'mologicheskie vedomosti [Ophthalmological bulletin] 2017; 10(1): 40-52. (In Russ.)

6. National Glaucoma Guidelines for Practitioners. Мoscow: GEOTAR-Media; 2019. (In Russ.)

7. Terrin N., Schmid C. H., Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. Journal of clinical epidemiology 2005; 58(9): 894-901.

8. Petrov S.Yu., Volzhanin A.V., Kravchik M.V., Mazurova Yu.V., Saparova L.M. Vliyanie tafluprosta na sutochnye kolebaniya oftal'motonusa pri pervichnoj otkrytougol'noj glaukome. [Effect of tafluprost on the diurnal intraocular pressure fluctuations in patients with primary open-angle glaucoma.] Nacional'nyj zhurnal glaukoma [National Journal of Glaucoma] 2018; 17(4): 91-96, doi: 10.25700/ NJG.2018.04.08 (In Russ.)

9. Antonov A.A., Vostruhin S.V., Volzhanin A.V. Vitkov A.A., Akimov A.M., Asinovskova I.I. Vliyanie analogov prostaglandinov na kolebaniya vnutriglaznogo davleniya pri izmenenii polozheniya tela. [Influence of prostaglandin analogues on intraocular pressure fluctuations in body position change.] Klinicheskaya oftal'mologiya [RMJ. Clinical ophthalmology] 2022; 22(2): 103-107, doi: 10.32364/2311-7729- 2022-22-2-103-107 (In Russ.)

10. Lim K.S., Nau C.B., O'Byrne M.M., Hodge D.O., Toris C.B., McLaren J.W., Johnson D.H. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008; 115(5): 790-795.e4, doi: 10.1016/j.ophtha.2007.07.002

11. Neacsu A.M. Receptors involved in the mechanism of action of topical prostaglandins. [Article in Romanian]. Oftalmologia 2009; 53 (2): 3-7.

12. Shah M.,   Lee G.,  Lefebvre D.R., Kronberg B.,  Loomis S.,  Brauner S.C., Turalba A.,  Rhee D.J.,  Freitag S.K.,  Pasquale L.R. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PloS one 2013; 8(5): e61638.

13. Egorova T.E. Prostaglandiny v lechenii glaukomy. [Prostaglandins in the treatment of glaucoma.] RMJ. Klinicheskaya oftal'mologiya [RMJ. Clinical ophthalmology] 2004; 5(3): 127-131. (In Russ.)

14. Yamamoto K., Sato K., Yukita M., Yasuda M., Omodaka K.,  Ryu M., Fujita K.,  Nishiguchi K.M., Machida S., Nakazawa T. The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. Journal of Neurochemistry 2017; 140(3): 495-508, doi: 10.1111/jnc.13902

15. Kurysheva N.I., Azizova O.A., Piryazev A.P. Sravnitel'naya harakteristika antioksidantnoj aktivnosti analogov prostaglandinov dlya mestnogo lecheniya glaukomy. [Comparison of antioxidant activity of prostaglandin analogues for topical glaucoma treatment.] Nacional'nyj zhurnal glaukoma [National Journal of Glaucoma] 2014; 13(4): 31-39. (In Russ.)

16. Egorov E.A. Nezhelatel'nye yavleniya gipotenzivnoj terapii glaukomy. [] RMJ. Klinicheskaya oftal'mologiya [RMJ. Clinical ophthalmology] 2011; 12(3): 111-113. (In Russ.)

17. European Glaucoma Society. Terminology and guidelines for glaucoma. 2th ed. Savona: Italy DOGMA; 2003.

18. Clinical Review Report: Preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost): (Laboratoires Théa): Indication: Reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 May. CADTH Common Drug Reviews.

19. Onufrijchuk O.N., Gazizova I.R., Kuroedov A.V., Seleznev A.V. Vliyanie na sostoyanie glaz pacientov s glaukomoj osnovnyh dejstvuyushchih veshchestv gipotenzivnyh kapel'. [The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients.] Tihookeanskij medicinskij zhurnal [Pacific medical journal] 2020; (3): 5-10. (In Russ.)

20. Pillunat L.E., Eschstruth P., Hsemeyer S., Thelen U., Foja C., Leaback R., Pfennigsdorf S. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clinical Ophthalmology 2016; 10: 1759-1765.

21. Kapur R., Osmanovic S., Toyran S., Edward D.P. Bimatoprost-Induced Periocular Skin Hyperpigmentation: Histopathological Study. Archive Ophthalmology 2005; 123: 1541-1546.

22. Law S.K. Bimatoprost in the treatment of eyelash hypotrichosis. Clinical Ophthalmology 2010; 26(4): 349-358, doi: 10.2147/opth.s6480

23. Johnstone M.A., Albert D.M. Prostaglandin-induced hair growth. Survey of Ophthalmology 2002; 47(1): S185-202, doi: 10.1016/s0039-6257(02)00307-7

24. Tsai J.C., Sivak-Callcott J.A., Haik B.G., Zhang J.,  McLean I.W. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. Journal of Glaucoma 2001; 10(5): 411-413, doi: 10.1097/00061198-200110000-00009

25. Alm A., Schoenfelder J., McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Archive of Ophthalmology 2004;122: 957-965, doi: 10.1001/ archopht.122.7.957

26. El Hajj Moussa W.G., Farhat R.G., Nehme J.C., Sahyoun M.A., Schakal A.R., Jalkh A.E., Pierre Abi Karam M.,  Georges Azar G. Comparison of efficacy and ocular surface disease index score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in glaucoma patients. Journal of Ophthalmology 2018:1319628. doi: 10.1155/2018/1319628

27. Filippopoulos T., Paula J.S., Torun N., Hatton M.P.,  Pasquale L.R.,  Grosskreutz C.L. Periorbital changes associated with topical bimatoprost. Ophthalmic Plastic and Reconstructive Surgery 2008; 24: 302-307.

28. Shah M., Lee G., Lefebvre D.R.,  Kronberg B., Loomis S.,  Brauner S.C., Turalba A.,  Rhee D.J.,  Freitag S.K.,  Pasquale L.R. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One 2013; 8(5): e61638. doi: 10.1371/journal.pone.0061638

29. Tappeiner C., Perren B., Iliev M.E., Frueh B.E., Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost – can bimatoprost cause enophthalmos? . Klinische Monblatter Augenheilkunde 2008; 225 (5): 443-445, doi: 10.1055/s-2008-1027362. (In Germ.)

30. Kim J.W. Topical prostaglandin analogue drugs inhibit adipocyte differentiation. Korean Journal of Ophthalmology 2014; 28(3): 257-264. doi: 10.3341/kjo.2014.28.3.257

31. Kim H.W., Choi Y.J., Lee K.W., Lee M.J. Periorbital changes associated with prostaglandin analogs in Korean patients. BMC Ophthalmology 2017; 17(1): 126, doi: 10.1186/s12886-017-0521-4

32. Aihara M., Shirato S., Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Japan Journal of Ophthalmology 2011; 55(6): 600-604, doi: 10.1007/s10384-011-0075-6

33. Maruyama K., Tsuchisaka A., Sakamoto J. Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients. Clinical Ophthalmology. 2013; 7:1441-1446, doi: 10.2147/OPTH.S47783

34. Maruyama K., Shirato S., Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. Journal of Glaucoma 014; 23: 160-163.

35. Inoue K., Shiokawa M., Wakakura M., Tomito G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. Journal of Glaucoma 2013; 22: 626-631.

36. Taketani Y., Yamagishi R., Fujishiro T., Igarashi M., Sakata R., Aihara M. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Investigative Ophthalmology and Visual Science 2014; 55(3): 1269-1276.

37. Miki T., Naito T., Fujiwara M., Araki R., Kiyoi R., Shiode Y., Fujiwara A. ,  Morizane Y. , Shiraga F. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One 2017; 12(7): e0181550, doi: 10.1371/journal.pone.0181550

38. Sakata R., Shirato S., Miyata K., Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Japan Journal of Ophthalmology 2013; 57: 179-184.

39. Yaoeda K., Fukushima A., Shirakashi M., Miki A., Fukuchi T. Factors associated with fluctuations in repeated measurements of intraocular pressure using the Goldmann applanation tonometer in Japanese patients with primary open-angle glaucoma. Clinical Ophthalmology 2018; 12: 1473-1478, doi:10.2147/OPTH.S174277

40. Park J., Cho H.K., Moon J.I. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol 2011; 55(1): 22-27, doi: 10.1007/s10384-010-0904-z

41. Neroev V.V., Gar'kavenko V.V., Salmin V.V. Spektrofluorimetricheskoe issledovanie zony limba u pacientov s pervichnoj otkrytougol'noj glaukomoj. [A spectrofluorimetric study of the limbal area in patients with primary open-angle glaucoma.] Rossijskij oftal'mologicheskij zhurnal [Russian ophthalmological journal] 2021; 14(4): 60-64, doi:10.21516/2072-0076-2021-14-4-60-64 (In Russ.)